Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      European primary care VE group
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam, The Netherlands : Elsevier Science
      Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
    • Subject Terms:
      COVID-19*/prevention & control ; COVID-19*/epidemiology ; COVID-19 Vaccines*/administration & dosage ; COVID-19 Vaccines*/immunology ; SARS-CoV-2*/immunology ; Primary Health Care* ; Vaccine Efficacy*; Humans ; Europe/epidemiology ; Female ; Male ; Middle Aged ; Adult ; Case-Control Studies ; Aged ; Young Adult ; Adolescent ; Vaccination/methods ; Vaccination/statistics & numerical data ; Immunization Programs
    • Abstract:
      In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September 2023 and January 2024. Using a test-negative case-control design, we estimated VE in the target group for COVID-19 vaccination overall and by time since vaccination. We included 1057 cases and 4397 controls. Vaccine effectiveness was 40 % (95 % CI: 26-53 %) overall, 48 % (95 % CI: 31-61 %) among those vaccinated < 6 weeks of onset and 29 % (95 % CI: 3-49 %) at 6-14 weeks. Our results suggest that COVID-19 vaccines administered to target groups during the autumn 2023 campaigns showed clinically significant effectiveness against laboratory-confirmed, medically attended symptomatic SARS-CoV-2 infection in the 3 months following vaccination. A longer study period will allow for further variant-specific COVID-19 VE estimates, better understanding decline in VE and informing booster administration policies.
      Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
    • Comments:
      Erratum in: Vaccine. 2024 Oct 3;42(23):126089. doi: 10.1016/j.vaccine.2024.06.056. (PMID: 38971666)
    • References:
      BMJ Evid Based Med. 2022 Dec;27(6):324-329. (PMID: 35338091)
      Vaccine. 2023 Nov 13;41(47):6904-6909. (PMID: 37872011)
      Vaccine. 2013 Apr 19;31(17):2165-8. (PMID: 23499601)
      Euro Surveill. 2012 Sep 27;17(39):. (PMID: 23041022)
      Lancet Infect Dis. 2023 Apr;23(4):435-444. (PMID: 36436536)
      MMWR Morb Mortal Wkly Rep. 2024 Feb 01;73(4):77-83. (PMID: 38300853)
      Lancet Infect Dis. 2024 Feb;24(2):e70-e72. (PMID: 38109919)
      Influenza Other Respir Viruses. 2023 Jan;17(1):e13069. (PMID: 36702797)
      Vaccine. 2024 Apr 11;42(10):2543-2552. (PMID: 37973512)
      J Clin Epidemiol. 1996 Dec;49(12):1373-9. (PMID: 8970487)
      Clin Infect Dis. 2022 Aug 24;75(1):e564-e571. (PMID: 35325923)
      Euro Surveill. 2024 Feb;29(7):. (PMID: 38362622)
      Lancet Respir Med. 2023 Dec;11(12):1089-1100. (PMID: 37898148)
      Cell Host Microbe. 2024 Mar 13;32(3):315-321.e3. (PMID: 38377995)
      JAMA Netw Open. 2024 Jul 1;7(7):e2419258. (PMID: 38949812)
    • Contributed Indexing:
      Keywords: COVID-19; Europe; Multicentre study; SARS-CoV-2; Test-negative design; Vaccine effectiveness
    • Accession Number:
      0 (COVID-19 Vaccines)
    • Publication Date:
      Date Created: 20240605 Date Completed: 20240711 Latest Revision: 20240913
    • Publication Date:
      20240914
    • Accession Number:
      PMC11252666
    • Accession Number:
      10.1016/j.vaccine.2024.05.067
    • Accession Number:
      38839521